Kamada (KMDA) Non-Current Assets (2012 - 2026)

Kamada (KMDA) posted quarterly Non-Current Assets of $183.8 million for Q1 2026, down 1.51% year-on-year from $186.6 million in Q1 2025, and down 1.0% on a QoQ basis from $185.6 million in Q4 2025.

Kamada (KMDA) Non-Current Assets (2012 - 2026) Analysis & Trends

Kamada (KMDA) has reported Non-Current Assets for 13 consecutive years, with $183.8 million the latest figure, recorded in Q1 2026.

  • Quarterly Non-Current Assets fell 1.51% year-over-year to $183.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $738.8 million (down 0.95% YoY) and the FY2025 annual result came in at $185.6 million, down 1.21% from the prior year.
  • Non-Current Assets fell to $183.8 million in Q1 2026 per KMDA's latest filing, from $185.6 million in the prior quarter.
  • Over the last five years, Non-Current Assets for KMDA reached as high as $354.7 billion in Q4 2023 and fell as low as $183.4 million in Q4 2022.
  • A 5-year average of $40.9 billion and a median of $185.6 million in 2025 frame the typical range for Non-Current Assets.
  • Annual changes were most pronounced in 2023 — Non-Current Assets jumped 193350.02% — and 2024, when it tumbled 99.95%.
  • Year by year, Non-Current Assets stood at $183.4 million in 2022, then soared by 193350.02% to $354.7 billion in 2023, then slumped by 99.95% to $187.9 million in 2024, then retreated by 1.21% to $185.6 million in 2025, then slipped by 1.0% to $183.8 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods registered $183.8 million, $185.6 million, and $184.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 36.78 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 26.33 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 8.68 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 79.20 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 3.84 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - 15.70 Bn
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 25.92 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 2.47 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 9.64 Bn
10 Kamada 401.22 Mn 328.07 Mn 19.12 Mn 183.79 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 183.79 Mn
Dec 31, 2025 185.64 Mn
Sep 30, 2025 184.48 Mn
Jun 30, 2025 184.90 Mn
Mar 31, 2025 186.61 Mn
Dec 31, 2024 187.91 Mn
Sep 30, 2024 186.80 Mn
Jun 30, 2024 184.61 Mn
Mar 31, 2024 185.37 Mn
Dec 31, 2023 354.74 Bn
Sep 30, 2023 336.90 Bn
Jun 30, 2023 184.71 Mn
Mar 31, 2023 316.66 Mn
Dec 31, 2022 183.37 Mn
Sep 30, 2022 319.50 Mn
Jun 30, 2022 185.53 Mn
Mar 31, 2022 186.93 Mn
Dec 31, 2021 188.62 Mn
Sep 30, 2021 37.58 Mn
Jun 30, 2021 37.00 Mn